BR100 Increased By (0.75%)
BR30 Increased By (1.08%)
KSE100 Increased By (0.82%)
KSE30 Increased By (0.89%)
AGHA 6.44 Increased By ▲ 0.06 (0.94%)
BECO 4.33 Decreased By ▼ -0.02 (-0.46%)
BML 62.90 Increased By ▲ 0.35 (0.56%)
BOP 31.42 Increased By ▲ 0.03 (0.1%)
CNERGY 11.90 Increased By ▲ 0.17 (1.45%)
CSIL 5.90 Decreased By ▼ -0.01 (-0.17%)
FCCL 62.29 Increased By ▲ 0.58 (0.94%)
FFL 14.87 Increased By ▲ 0.08 (0.54%)
FNEL 1.29 Increased By ▲ 0.05 (4.03%)
KEL 6.34 Increased By ▲ 0.02 (0.32%)
KOSM 5.90 No Change ▼ 0.00 (0%)
LOTCHEM 24.78 Increased By ▲ 0.09 (0.36%)
MLCF 106.03 Increased By ▲ 2.10 (2.02%)
NBP 174.59 Increased By ▲ 1.27 (0.73%)
NCPL 52.30 Increased By ▲ 0.47 (0.91%)
NPL 55.00 Increased By ▲ 0.97 (1.8%)
OGDC 319.93 Increased By ▲ 4.06 (1.29%)
PACE 9.33 Increased By ▲ 0.07 (0.76%)
PAEL 35.87 Increased By ▲ 0.29 (0.82%)
PIBTL 13.90 Increased By ▲ 0.24 (1.76%)
PPL 228.51 Increased By ▲ 2.44 (1.08%)
PRL 81.91 Increased By ▲ 1.63 (2.03%)
PTC 47.19 Increased By ▲ 0.55 (1.18%)
SSGC 24.01 Increased By ▲ 0.19 (0.8%)
TBL 9.26 Increased By ▲ 0.02 (0.22%)
TELE 7.53 Decreased By ▼ -0.02 (-0.26%)
TPL 25.00 Increased By ▲ 0.46 (1.87%)
TPLP 13.15 Increased By ▲ 0.16 (1.23%)
TREET 26.11 Increased By ▲ 0.13 (0.5%)
TRG 53.80 Increased By ▲ 0.47 (0.88%)
By

FRANKFURT: Swiss drugmaker Novartis raised its 2024 earnings guidance for the third time on Tuesday, driven by wider use of its prescription drugs such as psoriasis and arthritis drug Cosentyx.

In a statement on Tuesday, Novartis said it expects full-year core operating income, adjusted for one-off items, to grow by a “high teens” percentage, compared with a previous guidance of “mid- to high teens” percentage.

The group, which has cut jobs and spun off generic drugs business Sandoz to focus on new drug development, also posted better-than-expected third-quarter earnings, helped by revenue gains from anti-inflammation drug Cosentyx, among other factors.

Novartis aims for 5% annual sales growth through 2027

Quarterly adjusted core operating income gained 17% to $5.15 billion, beating an average analyst estimate of over $4.8 billion.

Quarterly Cosentyx sales gained 27% to $1.69 billion, helped by its recent approval to treat hidradenitis suppurativa, a painful acne-like skin condition.

Comments

Comments are closed for this article.